PowerSchool Holdings Inc (PWSC) News

Form 8-K - Current report

Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada

CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or...

Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024

CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]

Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]

Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]

Form 8-K - Current report

Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®

CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company...